no endothelial cell apoptosis. As mentioned previously, our study only examines one time point. It is possible that apoptosis occurred at an earlier time point than our assessment at the 14 day time point. Indeed, it has been shown previously that hindlimb unloading results in capillary loss in as little as 5 days. If changes in endothelial cell number, and therefore total vasculature, are occurring by 57 days it may not be surprising that evidence of apoptosis has been lost by the end of the study. That is, perhaps apoptosis has already occurred, the cells cleared from the tissue, and the architecture of 21147071 the vascular network at 14 days has already returned to a new steady state condition absent of apoptotic nuclei. We have yet to elucidate this and more experimentation is needed to determine exactly when apoptosis and regression is occurring. Summary In conclusion, we provide evidence for the importance of TSP1/CD36 pathway in regulating basal skeletal muscle YM-155 capillarity by showing that a chronic dosage of a TSP-1 mimetic for the CD36 pathway decreases skeletal muscle capillarity and VEGF expression. We did not find any differences in the VEGFR-2 expression or its phosphorylation status, nor was there greater skeletal muscle apoptosis. These data show that, despite the multifunctional effects of TSP-1 and its CD36 receptor, the primary consequence of elevating circulating TSP-1 relates to its anti-angiogenic function. These data may be useful in exploring therapeutic interventions for individuals with skeletal muscle dysfunction resulting from capillary regression. ~~ ~~ In response to the global HIV epidemic, a public health approach to antiretroviral therapy has been widely implemented in low- and middle-income countries. In 2010, 6.6 million adults and children received ART, representing a 22-fold increase from 2001. The rapid scale-up of ART is an impressive public health achievement that has led to dramatic declines in HIV related morbidity and mortality. Frequently reported outcomes for populations receiving ART include the number of: patients alive and on ART, deaths, patients transferring care from one facility to another, patients stopping ART but remaining in care, and patients lost to follow-up. LTFU is a generic term referring to patients who initiate ART but who have unknown treatment outcomes. These unknown treatment outcomes may be divided into 3 general categories: unreported deaths, unknown transfer of care to a different facility without documentation, and disengagement from care. Patient tracing is a commonly used method to improve retention in care and reduce unknown outcomes. Typically in LMICs, tracing involves contacting patients by telephone, physically visiting their place of residence, or a combination 16873882 of both. Tracing patients has two potential benefits: 1) linking patients who are disengaged from Physical Tracing on LTFU, Mortality and Retention care back into the health care system, and 2) improved classification of unknown outcomes. By minimizing the number of individuals who disengage from care, programs optimize care by maintaining the greatest possible number of patients on ART, thus decreasing mortality and complications of immunodeficiency. Additionally, patients who have disengaged from care are at increased risk of transmitting HIV due to uncontrolled viremia and for 
the selection of drug resistance by virtue of ART treatment interruptions. Maximizing the number of patients alive and receiving ART
